Intravenous Lidocaine and the Unfinished Comparison
An editorial reading of an interrupted comparison: examine the measurements before imagining the verdict.
THE HIVEPROSPECT WEEKLY
Drug discoveries, difficult failures and the business decisions between them.
An editorial reading of an interrupted comparison: examine the measurements before imagining the verdict.
Editorial inference: this terminated trial warrants a careful reading of the regimen comparison, not a declaration that pemetrexed has been abandoned.
ODYSSEY-HCM offers a useful exercise in keeping a stopping reason, endpoint results and unanswered questions in their proper places.
An editorial interpretation of what RAGNAR intended to test, and why its clinical question remains open.
An editorial reading of trial endpoints, reported outcomes, and the questions to ask before discussing a development opportunity.
Editorial inference: understanding the terminated registry requires an account of treatment exposure across its two cohort pathways.
Inference: the useful question is what the experiment could establish, and which answers still require patient results.
More potent in a recombinant enzyme assay does not mean better for patients. The safety record explains why that distinction matters.